Pharmaceuticals
Cambrex Announces Sale of Drug Product Business Unit
EAST RUTHERFORD, N.J., Nov. 2, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), has today completed the sale of its Drug Product Business Unit toWilmington, Delaware based Noramco. Cambrex's Drug Product business provides product developme...
2023-11-02 18:00
3010
Xinhua Silk Road: 54th Zhangshu National Traditional Chinese Materia Medica Trade Fair kicks off in E. China's Jiangxi
BEIJING, Nov. 2, 2023 /PRNewswire/ -- The 54th Zhangshu National Traditional
Chinese Materia Medica Trade Fair was held recently in Zhangshu, a county-level
city in eastChina's Jiangxi Province.
2023-11-02 14:21
3675
TraceLink MINT Wins 2023 Pharma Innovation Award: 100% End-to-End Supply Chain Digitalization is Now Within Reach
100% End-to-End Supply Chain Digitalization is Now Possible with Proven Network Orchestration Capability BOSTON, Nov. 2, 2023 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company enabling end-to-end product orchestration by connecting more than 291,000 healthcare and life...
2023-11-02 05:22
2712
Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction
The Group is Advancing the Program to a Phase II Clinical Study Data presented at the 2023 Fall Clinical Dermatology Conference HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Nov. 1, 2023 /PRNewswire/ --Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries,...
2023-11-01 22:07
3847
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China
* CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commercialization of nofazinlimab (anti-PD-1 antibody) in mainlandChina. CStone to retain the rights to nofazinlimab outside mainland China. * This partnership will combine the strengths of CStone a...
2023-11-01 18:10
5291
Soterios Pharma completes Phase II enrolment for STS-01 in mild / moderate (patchy) alopecia areata
LONDON, Nov. 1, 2023 /PRNewswire/ -- Soterios Pharma, a privately held clinical-stage pharmaceutical company, announced today that it has completed target enrolment for its Phase II trial with STS-01 for mild / moderate (patchy) alopecia areata. Final results of the study are anticipated to be ...
2023-11-01 09:05
1579
Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting
SHANGHAI and HONG KONG, Nov. 1, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer...
2023-11-01 08:30
2466
BioLineRx Entered Exclusive License Agreement to Motixafortide in Asia, Advised by MSQ Ventures
NEW YORK, Oct. 31, 2023 /PRNewswire/ -- MSQ Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the deve...
2023-10-31 21:00
5087
YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
GAITHERSBURG, Md., Oct. 31, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-10-31 20:30
2384
Select the Right Medical-Grade TPU：ICP DAS - BMP Launches a New TPU Series at COMPAMED & IPF Japan 2023
HSINCHU, Oct. 31, 2023 /PRNewswire/ -- ICP DAS – Biomedical Polymers, Asia's first medical-grade TPU (thermoplastic polyurethane) manufacturer and supplier, will be exhibiting at COMPAMED inGermany and IPF in Japan in November and December 2023. The company proudly presents its new Arothane™ ARP-...
2023-10-31 16:38
3782
Biotechnology Start-Up Psylo Wins Hello Tomorrow APAC Deep Tech Competition in Singapore
SINGAPORE, Oct. 31, 2023 /PRNewswire/ -- Psylo, a biotechnology start-up pioneering the development of next-generation serotonergic agents for the treatment of central nervous system (CNS) disorders, today announced that it won the Hello Tomorrow APAC deep tech competition held inSingapore. The ...
2023-10-31 15:42
2865
CStone Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma, the First Anti-PD-1/PD-L1 mAb Approved for this Indication
* Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL) indication. * This marks sugemalimab's third indication approved in China following Stage III and IV non-small cell lung cancer (NSCLC) and the ...
2023-10-31 10:16
3892
LifeSpan Vision Ventures Invests in NaNotics
NORWALK, Conn., Oct. 31, 2023 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm dedicated to longevity biotech, today announced an investment in NaNotics LLC. This preclinical-stage biopharmaceutical company is developing NaNots™, novel subtractive nanoparticles that treat disease by c...
2023-10-31 02:26
4680
New Clinical Data Point to Use of GlycoMark as Biomarker of SGLT-2 Diabetes Drug Effectiveness and Compliance
RALEIGH, N.C., Oct. 30, 2023 /PRNewswire/ -- Precision Diabetes, Inc. announces new studies that show that the GlycoMark blood test, which measures 1,5-anhydroglucitol, may be useful for evaluating short-term effectiveness and assessing patient compliance of SGLT-2 inhibitor diabetes drugs. SGLT-...
2023-10-30 20:00
1686
Rational Vaccines and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Announce Collaboration to Develop Herpes Vaccines in China
The partnership will further therapeutic and prophylactic vaccine development for the Chinese market and beyond. WOBURN, Ma. and SHENZHEN, China, Oct. 30, 2023 /PRNewswire/ -- Rational Vaccines (RVx) and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (MH) announced they have reached an agreemen...
2023-10-30 19:30
2227
Aquinnah Pharmaceuticals Advances Oral Small Molecule Program Targeting Alzheimer's and Other Tauopathy Diseases
New preclinical data presented at CTAD demonstrates exciting potential for a new drug approach for Alzheimer's disease, reducing brain tau pathology by ~70% CAMBRIDGE, Mass., Oct. 30, 2023 /PRNewswire/ -- Aquinnah Pharmaceuticals announced preclinical research findings for a novel therapeutic des...
2023-10-30 19:00
2157
First Patient Enrolled in Phase III Clinical Trial of Boan Biotech's Nivolumab Injection
YANTAI, China, Oct. 30, 2023 /PRNewswire/ -- Boan Biotech (6955.HK) announced today that the first patient in Phase III clinical trial of its Nivolumab Injection (BA1104) inChina has been enrolled. BA1104 is the first biosimilar to Opdivo® to undergo a Phase III study in China. Nivolumab is a mo...
2023-10-30 14:51
4548
Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity
* Mazdutide demonstrates its differentiated advantages as a novel dual agonist of GLP-1 and GCG receptor with superior weight loss efficacy, significant improvement in a series of cardiometabolic indicators (waist circumference, blood pressure, liver enzyme, triglyceride, low-density lipoprote...
2023-10-30 08:00
5340
Samyang Holdings Presents Clinical Cases of 'Lafullen® and Croquis®' at KOAT Academic Conference
* Presentation of "Lafullen®" and "Croquis®" Procedures and Clinical Cases... Confirming Product Excellence and Safety * Biodegradable Polymer Filler "Lafullen®" Maintains Natural Volume for 2 Years * "Croquis®" Lifting Threads with Samyang' expertise in Global Biodegradable Suture Threa...
2023-10-30 08:00
3239
Henlius Announces NMPA Approvals of Two ADC Candidates for IND
SHANGHAI, Oct. 27, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that the investigational new drug (IND) applications of HLX42 for Injection, a novel EGFR-targeting antibody-drug conjugate (ADC) as well as HLX43, a novel PD-L1-targeting ADC, have been approved by the Na...
2023-10-27 20:16
4878
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 293 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
8928
QIVIKA to Launch Smart Scope on Kickstarter, Bringing a Professional Long-Range Experience to Day-and-Night Exploration
2026-09-12 09:00
8141
Temporal Raises $550 Million in Series E Round: NYSE Content Update
2026-09-14 21:14
7362
